Compugen (CGEN) News Today $2.25 +0.13 (+6.13%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Compugen (NASDAQ:CGEN) Now Covered by Analysts at OppenheimerJanuary 14, 2025 | americanbankingnews.comOppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)January 14, 2025 | markets.businessinsider.comCompugen initiated with an Outperform at OppenheimerJanuary 13, 2025 | markets.businessinsider.comCompugen (NASDAQ:CGEN) Earns Outperform Rating from Analysts at OppenheimerOppenheimer began coverage on shares of Compugen in a research note on Monday. They set an "outperform" rating and a $4.00 price objective on the stock.January 13, 2025 | marketbeat.comCompugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsJanuary 8, 2025 | prnewswire.comCompugen Ltd.January 3, 2025 | wsj.comThe past five years for Compugen (NASDAQ:CGEN) investors has not been profitableDecember 26, 2024 | uk.finance.yahoo.comCompugen Bolsters Cancer Therapy Portfolio with New PatentNovember 28, 2024 | markets.businessinsider.comCompugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNovember 27, 2024 | prnewswire.comRoche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trialNovember 26, 2024 | msn.comCompugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in OctoberCompugen Ltd. (NASDAQ:CGEN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average trading volume of 225,400 shares, the days-to-cover ratio is currently 5.6 days.November 16, 2024 | marketbeat.comCompugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?November 16, 2024 | finance.yahoo.comCompugen’s Financial Surge and Promising Drug TrialsNovember 14, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Compugen (CGEN)November 14, 2024 | markets.businessinsider.comCompugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comCompugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...November 13, 2024 | finance.yahoo.comCompugen Ltd. (CGEN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comCompugen Ltd.: Compugen Reports Third Quarter 2024 ResultsNovember 12, 2024 | finanznachrichten.deCompugen Reports Third Quarter 2024 ResultsNovember 12, 2024 | prnewswire.comCompugen to Participate in Stifel 2024 Healthcare ConferenceNovember 11, 2024 | prnewswire.comCompugen (CGEN) Receives a Buy from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comCompugen (CGEN) to Release Earnings on TuesdayCompugen (NASDAQ:CGEN) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641326)November 5, 2024 | marketbeat.comCompugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024November 5, 2024 | prnewswire.comShort Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1%Compugen Ltd. (NASDAQ:CGEN - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 1,550,000 shares, a decrease of 17.1% from the September 30th total of 1,870,000 shares. Based on an average daily trading volume, of 231,800 shares, the short-interest ratio is currently 6.7 days.October 29, 2024 | marketbeat.comCompugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024October 29, 2024 | prnewswire.comCompugen to Present New Clinical Data at SITC 2024October 7, 2024 | prnewswire.comBiomerica (NASDAQ:BMRA) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comCompugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short InterestCompugen Ltd. (NASDAQ:CGEN - Get Free Report) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 1,880,000 shares, a growth of 15.3% from the August 31st total of 1,630,000 shares. Based on an average daily volume of 256,200 shares, the days-to-cover ratio is currently 7.3 days.September 29, 2024 | marketbeat.comCompugen Ltd. (NASDAQ:CGEN) Short Interest Down 5.8% in AugustCompugen Ltd. (NASDAQ:CGEN - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,630,000 shares, a decrease of 5.8% from the August 15th total of 1,730,000 shares. Based on an average trading volume of 266,200 shares, the short-interest ratio is currently 6.1 days.September 18, 2024 | marketbeat.comGSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trialSeptember 14, 2024 | msn.comCompugen to Present at Single Cell Genomics 2024 ConferenceSeptember 9, 2024 | prnewswire.comCompugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | prnewswire.comCompugen LtdAugust 27, 2024 | money.usnews.comTruist Financial Keeps Their Buy Rating on Compugen (CGEN)August 16, 2024 | markets.businessinsider.comCompugen (NASDAQ:CGEN) Lifted to "Buy" at StockNews.comStockNews.com upgraded shares of Compugen from a "hold" rating to a "buy" rating in a report on Thursday.August 15, 2024 | marketbeat.comCompugen Ltd. (CGEN)August 13, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings ForecastsAugust 11, 2024 | finance.yahoo.comCompugen Ltd. (CGEN) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comCompugen: Strong Buy on Promising Trials, Strategic Alliances, and Solid FinancialsAugust 9, 2024 | markets.businessinsider.comCompugen (NASDAQ:CGEN) Cut to Hold at StockNews.comStockNews.com cut shares of Compugen from a "buy" rating to a "hold" rating in a research report on Wednesday.August 7, 2024 | marketbeat.comCompugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?August 7, 2024 | finance.yahoo.comCompugen Reports Second Quarter 2024 ResultsAugust 6, 2024 | prnewswire.comCompugen Q2 2024 Earnings PreviewAugust 6, 2024 | msn.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | benzinga.comCompugen (CGEN) Scheduled to Post Quarterly Earnings on TuesdayCompugen (NASDAQ:CGEN) will be releasing earnings before the market opens on Tuesday, August 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=611417)July 30, 2024 | marketbeat.comCompugen Ltd.: Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 29, 2024 | finanznachrichten.deCompugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 29, 2024 | prnewswire.comStifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)July 23, 2024 | markets.businessinsider.comCompugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024July 23, 2024 | prnewswire.comStockNews.com Upgrades Compugen (NASDAQ:CGEN) to "Buy"StockNews.com raised Compugen from a "hold" rating to a "buy" rating in a research note on Wednesday.June 19, 2024 | marketbeat.com Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Media Mentions By Week CGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEN News Sentiment▼0.320.44▲Average Medical News Sentiment CGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEN Articles This Week▼32▲CGEN Articles Average Week Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bicara Therapeutics News Prothena News Dianthus Therapeutics News CorMedix News uniQure News 89bio News Cullinan Therapeutics News LENZ Therapeutics News Pharming Group News Arbutus Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
